Annamycin is a small molecule commercialized by Moleculin Biotech, with a leading Phase II program in Relapsed Acute Myeloid Leukemia. According to Globaldata, it is involved in 11 clinical trials, of which 4 were completed, 3 are ongoing, 3 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Annamycin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Annamycin is expected to reach an annual total of $54 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
L-Annamycin is under development for the treatment of relapsed or refractory acute myelogeneous leukemia (AML), metastatic lung cancer, metastatic melanoma, soft-tissue sarcomas with pulmonary metastases, metastatic lung sarcoma, reticulosarcoma, metastatic pancreatic cancer (liver mets/pancreatic), liposarcoma, leiomyosarcoma, synovial sarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, malignant peripheral nerve sheath tumour, malignant solitary fibrous tumour, and pleomorphic RMS and metastatic osteosarcoma. The drug candidate is administered intravenously. L-Annamycin is a liposome nanoparticle formulation of annamycin, a second generation anthracycline. It is a liposome-encapsulated form of the semi-synthetic doxorubicin analogue annamycin with antineoplastic activity. It acts by targeting DNA topoisomerase II. It was under development for the treatment of relapsed and refractory acute lymphocytic leukemia (ALL).
Moleculin Biotech Overview
Moleculin Biotech (MBI) is a clinical stage pharmaceutical company. It offers development of novel drugs for oncology. The company’s lead product candidate Annamycin is an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). It also develops WP1066, an immuno-stimulating STAT3 inhibitor, for treatment of brain tumors, pancreatic cancer and AML; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company works in collaboration with The University of Texas MD Anderson Cancer Center, and Dermin SP ZOO to develop its product portfolio. MBI is headquartered in Houston, Texas, the US.
The operating loss of the company was US$23 million in FY2021, compared to an operating loss of US$19.7 million in FY2020. The net loss of the company was US$15.9 million in FY2021, compared to a net loss of US$17.4 million in FY2020.
For a complete picture of Annamycin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.